Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Reorg: Centers Will Report Directly To Gottlieb; 'Flattened' Structure Will Make Future Political Transitions Easier

Executive Summary

Principal Deputy Commissioner Sherman remains top policy guru and will oversee consolidation of functions currently scattered throughout FDA into the Office of Operations.

Advertisement

Related Content

US FDA's New Global Office Aims To Elevate and Enhance Agency’s Role On World Stage
Sharpless Calls For A Nimble, Flexible, More Efficient US FDA
Gottlieb's Greatest Strength As US FDA Commissioner? Stability
Norman Sharpless Will Arrive At US FDA With Many Challenges Awaiting
US FDA Reorg: Defining The “Central” Purpose Of A Commissioner
US FDA Reorg Emphasizes Office of Therapeutic Biologics and Biosimilars
Gottlieb Touts US FDA's Organizational Structure For Advancing Policies During His Tenure
Office Of New Drugs Reorg Is Bigger Than Expected: US FDA Adds 11 Review Divisions
US FDA Commissioner Gottlieb Sees His Job As A Race Against The Clock
Gottlieb Adds A No. 2: Sherman Is US FDA Principal Deputy Commissioner

Topics

Advertisement
UsernamePublicRestriction

Register

PS123527

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel